Akero, AKRO
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc.with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors
NDAQ:AKRO) The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) investors co
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
If you suffered losses exceeding $75,000 investing in Akero stock or options between September 13, 2022 and October 9, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/AKRO.
AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors Can Join the Class Action Lawsuit!
Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors Can Join the Class Action Lawsuit!
Class Action Announcement for Akero Therapeutics, Inc. (AKRO): A Securities Class Action Lawsuit Has Been Filed Against Akero Therapeutics, Inc.
RADNOR, PA / ACCESSWIRE / May 2, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP( informs investors that a securities class
Business Wire7d
AKERO THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline ...
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until ...
BioSpace14d
Opinion: Akero and Madrigal Face Off in the MASH Space
While Madrigal Pharmaceuticals secured the first FDA drug approval for metabolic dysfunction–associated steatohepatitis, ...
Morningstar3d
Akero Therapeutics, Inc. (AKRO) Investor Notice: Robbins LLP Reminds Stockholders of the Akero Therapeutics, Inc. Class Action
Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Akero Therapeutics, Inc. (NASDAQ: AKRO) securities ...
Yahoo Finance6d
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...